articleThe Lancet OncologyJul 30, 2016Closed access

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

PAPaolo A. AsciertoGAGrant A. McArthurBDBrigitte DrénoVAVictoria AtkinsonGLGabrielle Liszkay

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · Peter MacCallum Cancer Centre · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,003
total citations
FWCI
58.14
Percentile
100%
References
29
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Vemurafenib
  • Medicine
  • Placebo
  • Internal medicine
  • Population
  • Melanoma
  • Oncology
  • Metastatic melanoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding